• 13585831301
  • 021-59541103 021-60443211
  • 3004967995

Palbociclib (PD0332991) Isethionate

  • 產品貨號:CS-01Y70923
  • 產品價格:電議
  • 產品產地:進口、國產
  • 包裝類型:10mM (in 1mL DMSO) 10mg 25mg 50mg
  • 采購熱度:233
  • 庫存:100
  • CAS號:827022-33-3
  • 方法:
  • 含量:>98.00%
  • 品牌名稱:莼試
  • 分子式:C24H29N7O2.C2H6O4S
  • 分子量:573.66

簡介內容:質量保證、價格優(yōu)惠

在線訂購  免費訂購熱線:021-59541103 021-60443211

標簽:Palbociclib (PD0332991) Isethionate 

產品目錄

聯(lián)系我們

聯(lián)系人:高小姐

電話:021-59541103 021-60443211

手機:13585831301

Q Q: 3004967995

Email:3004967995@qq.com

詳細地址:上海嘉定區(qū)嘉羅公路1661

商品詳情購物流程代測服務付款方式常見問題

化學性質:                                                                                                             

規(guī)格

10mM (in 1mL DMSO) 10mg 25mg 50mg

CAS

827022-33-3

別名

Palbociclib Isethionate

化學名

6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one;2-hydroxyethanesulfonic acid

分子式

C24H29N7O2.C2H6O4S

分子量

573.66

溶解度

28.7mg/mL in DMSO

儲存條件

Store at -20°C

General tips

For obtaining a higher solubility , please warm the tube at 37 and shake it in the ultrasonic bath for a while.

Shipping Condition

Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

 

產品描述:                                                                                                            

IC50: Palbociclib is an orally active, potent and highly selective inhibitor of CDK4 and CDK6, with IC50 values for CDK4/cyclinD1, CDK4/cyclinD3 and CDK6/cyclinD2 of 11, 9 and 15 nmol/l, respectively.

Cyclin-dependent kinases (CDKs) are a family of protein kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. A cyclin-dependent kinase inhibitor (CKI) is a protein that interacts with a cyclin-CDK complex to block kinase activity, usually during G1 or in response to signals from the environment or from damaged DNA. Palbociclib is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.

In vitro: Half-maximal inhibitory concentrations (IC50) of PD-0332991 were determined with cell line proliferation assays. Resutls showed that IC50 values for PD-0332991 ranged from 25.0 nM to 700 nM, and the agent demonstrated G0/G1 cell-cycle arrest, induction of late apoptosis, and blockade of RB phosphorylation. Through genotype and expression data p16, p15 and E2F1 were identified as having significant association between loss and sensitivity to PD-0332991: p16 (p=0.021), p15 (p=0.047), and E2F1 (p=0.041) [1].

In vivo: Oral administration of PD 0332991 to mice bearing the Colo-205 human colon carcinoma produces marked tumor regression. Therapeutic doses of PD 0332991 cause elimination of phospho-Rb and the proliferative marker Ki-67 in tumor tissue and down-regulation of genes under the transcriptional control of E2F. The results indicate that inhibition of Cdk4/6 alone is sufficient to cause tumor regression and a net reduction in tumor burden in some tumors [2].

Clinical trial: In a phase 2 trial reported at the April 2014 annual meeting of the American Association for Cancer Research, the addition of palbociclib to letrozole was shown to significantly slow the progression of advanced cancer (median progression-free survival increased from 10.2 months to 20.2 months), but was not shown to have a statistically significant effect on increasing patients' overall survival times. A potentially confirmatory phase 3 trial, PALOMA-2, has fully enrolled patients. The drug received an accelerated approval from the Food and Drug Administration on February 3, 2015, as a treatment (in combination with letrozole) for patients with estrogen receptor-positive advanced breast cancer (http://en.wikipedia.org/wiki/Palbociclib).

特別提醒:                                                                                                              

1. 本產品僅供科研使用。請勿用于醫(yī)藥、臨床診斷或治療,食品及化妝品等用途。請勿存放于普通住宅區(qū)。

2. 為了您的安全和健康,請穿好實驗服并佩戴一次性手套和口罩操作。

原創(chuàng)作者:上海莼試生物技術有限公司

在線咨詢

留言注意事項:

1.遵守中華人民共和國有關法律、法規(guī),尊重網(wǎng)上道德,承擔一切因您的行為而直接或間接引起的法律責任。

2.請您真實的反映產品的情況,不要捏造、誣蔑、造謠。如對產品有任何疑問,也可以留言咨詢。

3.未經本站同意,任何人不得利用本留言簿發(fā)布個人或團體的具有廣告性質的信息或類似言論。

    您感興趣的產品*
    您的單位*
    聯(lián)系人*
    聯(lián)系電話*
    詳細地址*
    常用郵箱*
    請輸入您對我們的意見或建議*
    驗證碼*

同類產品

訂購流程

訂貨流程

產品訂購說明:

  

1、報價含普票、運費。

2、常用試劑備貨充足,除對溫度要求極其嚴格的產品當天可發(fā)貨。

  

3、進口原裝產品要3-6周的貨期,詳細情況請咨詢客服。

  

4、訂貨時間為工作日每周一至周五16:00之前。

  

5、如需代為檢測,標本對環(huán)境溫度高,可聯(lián)系客服安排專人取樣(限省內客戶)。

  

6、代測免收代測費,一周出結果。

7、產品因運輸途中包裝破損請拒絕簽收,做退回。我們將在24小時之內為您補發(fā) 損壞產品。

8、如因單位財務制度原因,可申請先發(fā)貨,報賬后付款(此條款僅限醫(yī)院、學校信譽良好客戶)。

付款方式

普票匯款信息

  

賬 戶 名:上海生物

開 戶 行:中國銀行山東省分行營業(yè)部

  

賬 號:2169 2341 6278

 為方便廣大客戶辦理貨款我公司提供多個銀行的賬戶,學校、醫(yī)院客戶購買產品如因單位財務制度原因可先發(fā)貨待報賬后匯款,請及時告知銷售人員已做具體操作。